ReviewCells2023
Personalizing Care for Critically Ill Adults Using Omics: A Concise Review of Potential Clinical Applications.
Review in Cells, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Metabolomic Signatures of Biotrauma Associated with Mortality in ICU Patients Requiring Invasive Mechanical Ventilation and ECMO.Metabolites · 2026Article
- Current and novel biomarkers in cardiogenic shock.European journal of heart failure · 2025Review
- Anesthetic-mediated cardioprotection: from molecular mechanisms to clinical translation challenges.Frontiers in physiology · 2025Review
- New approaches to acute kidney injury.Clinical kidney journal · 2024Article
- Discovery of Delirium Biomarkers through Minimally Invasive Serum Molecular Fingerprinting.Metabolites · 2024Article
- Role of the Gut Bacteria-Derived Metabolite Phenylacetylglutamine in Health and Diseases.ACS omega · 2024Review
- Serum Metabolomic Profiles in Critically Ill Patients with Shock on Admission to the Intensive Care Unit.Metabolites · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current guidelines for critically ill patients use broad recommendations to promote uniform protocols for the management of conditions such as acute kidney injury, acute respiratory distress syndrome, and sepsis. Although these guidelines have enabled the substantial improvement of care, mortality for critical illness remains high. Further outcome improvement may require personalizing care for critically ill patients, which involves tailoring management strategies for different patients. However, the current understanding of disease heterogeneity is limited. For critically ill patients, genomics, transcriptomics, proteomics, and metabolomics have illuminated such heterogeneity and unveiled novel biomarkers, giving clinicians new means of diagnosis, prognosis, and monitoring. With further engineering and economic development, omics would then be more accessible and affordable for frontline clinicians. As the knowledge of pathophysiological pathways mature, targeted treatments can then be developed, validated, replicated, and translated into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.